Should I buy Regeneron Pharmaceuticals (REGN) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (383 calls tested). It aims for $930 (+24 %), call made on October 2, 2026, maturing on October 2, 2027 (12 d ago).
Firm-by-firm track record on Regeneron Pharmaceuticals
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 67 % | +29.9 % | 9 | $930 +23% |
| Citigroup | 75 % | +22.2 % | 8 | $740 -2% |
| BMO Capital | 77 % | +18.6 % | 13 | $730 -3% |
| Argus Research | 75 % | +17.6 % | 8 | $850 +13% |
| Oppenheimer | 79 % | +16.2 % | 14 | $865 +15% |
| Guggenheim | 70 % | +16.2 % | 10 | $1,030 +37% |
| Morgan Stanley | 80 % | +13.7 % | 20 | $779 +3% |
| HC Wainwright & Co. | 80 % | +13.6 % | 5 | $844 +12% |
✅ Reasons to believe
- 72% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
- Median price target $837, i.e. +11% from the current price ($753).
- The most reliable firm on REGN, Morgan Stanley (80% hit rate, 20 scored calls), targets $779 (call made on October 7, 2026, maturing on October 7, 2027) (+3%) in its most recent call, and $769 (call made on February 2, 2026, maturing on February 2, 2027) (+2%) in the one coming due soonest.
- Reasonable valuation (P/E ~19) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 18 ratings, 5 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on REGN
Median target $837 (+11%) · 18 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Regeneron Pharmaceuticals now?
We won't decide for you. The facts: 72% of analysts rate it a buy, median target $837 (+11%), and Morgan Stanley (most reliable on REGN, 80%) targets $779. Weigh that against valuation (P/E ~19). This is not personalized advice.
Is it too late to invest in Regeneron Pharmaceuticals?
Not according to analysts: the median target ($837) is still +11% above the current price ($753) (most reliable on REGN: Morgan Stanley, 80%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Regeneron Pharmaceuticals still worth investing in?
It depends on the gap between the price ($753) and its estimated value: analysts target $837 on median (+11%), with 72% buys (most reliable on REGN: Morgan Stanley, 80%). Cross-check with their real reliability on REGN and the cautions above. Information, not advice.
What's the main risk in buying REGN?
The consensus is not unanimous: of 18 ratings, 5 are neutral.
→ Go deeper: the full Regeneron Pharmaceuticals profile (consensus, analyst reliability, price target, performance).